FORT WORTH, Texas, Oct. 22, 2014 /PRNewswire/ -- MedHab, LLC, a privately held athletic and medical device company focused on the development of unique rehabilitative and sport-enhancing tools, announced today the company has established a partnership with Olympic champion and world record holder, Michael Johnson, and his athletic training organization, Michael Johnson Performance, Inc., to enhance the functionality of MedHab's lead device, RPM2. RPM2, which is available in three different formats for runners, cyclers and triathletes, developed to enhance athletic performance by objectively identifying deficiencies in athletes' gait, range of motion, pressure, power and cycling mechanics. A historically costly process for measuring each of these aspects of training, RPM2 consolidates these features into a single, easy-to-use device by including multiple tools such as a built-in power meter, which on its own can cost consumers thousands of dollars.
"We're delighted to have the expert insights available from Michael and the MJP team, as we aim to improve our novel device designed to help athletes achieve peak performance and potentially avoid injuries related to improper gait when training and competing," said Johnny Ross, president and CEO of MedHab and inventor of RPM2. "Our primary goal with RPM2 is to ensure athletes and their trainers are provided with an accurate and cost-efficient method of assessing bilateral equivalence. Not only can deficiencies in bilateral equivalence detract from overall athletic performance if not addressed proactively, injuries that occur when athletes aren't performing in a bilaterally equivalent manner can also result. Because gait analysis has historically been a highly overlooked and expensive aspect of training, we believe RPM2 will enable a greater number of athletes to achieve optimal performance. Our goal as a company is to leverage relationships, such as the relationship with MJP, to further enhance the capabilities of RPM2 to provide benefits to all athletes."
Bilateral deficiency is marked by differentiating levels of strength between two sides of the body. Because of the significant expertise and costs associated with examining this aspect of training, it is often overlooked until an injury occurs.
RPM2 is a wireless, remote monitoring, pressure sensing foot-bed device that is used for sports performance enhancement. The system consists of shoe inserts, each embedded with various sensors and a microcontroller, which provides data on athletes' gait, range of motion, power and pressure distribution so deficiencies in bilateral movement can be corrected and optimized.
In addition to the standard running model, RPM2 offers cycling technology that is used on its own and is also built-in to a triathlete version of the system. Among the benefits offered by RPM2 Cycling and Triathlete are four different modes, including distance, time trial, interval and sprint. An integral feature of RPM2 is a built-in power meter included in each model of the device. While power meters have historically been expensive training tools, the availability of RPM2 will now offer coaches and athletes the benefits of power meters at a significantly reduced price while simultaneously providing many additional key measurements important for athletes as they improve how they train and compete.
Combining the features of both the cycling and running versions into the RPM2 Triathlete model offers the most cost effective way to objectively test an athlete's bilateral deficiency with one easy to use device. This allows coaches and trainers to make the appropriate changes to an athlete's training regimen to help enhance their performance based on objective data.
MedHab is excited to be working with Michael Johnson, and Michael Johnson Performance, in offering this unique device to athletes. Known as the "fastest man in the world," During his 11-year career, Michael established a record of 13 Olympic and World Championship gold medals. He represented the U.S. in the Olympics on three occasions: Barcelona in 1992, winning gold in the 4 X 400-meter relay; Atlanta in 1996, winning gold at 200 meters and 400 meters; and Sydney in 2000, winning gold again at 400 meters. After retiring in 2001, Michael founded Michael Johnson Performance, a global athletic training organization dedicated to helping athletes achieve their full athletic potential. MJP is recognized as a world leader in the development and improvement of athleticism of athletes of all sports, ages, and abilities from youth athletes to some of the most recognized professional athletes in the world.
Regarding RPM2, Michael remarked, "We tested RPM2 on a number of our team's professional coaches and believe this system will provide us with valuable feedback when monitoring our clients' performances. Our coaches are well trained in helping athletes improve their skills; however, we're now able to more objectively observe the mechanics involved in our clients' movements to enhance their abilities and avoid injury. RPM2 will be used as a regular part of our athletes' training. Having competed professionally, I can personally attest to the importance of ensuring bilateral equivalence for optimal performance."
RPM2 was developed from technology intended to remotely monitor patients undergoing physical therapy. Johnny Ross, inventor of RPM2, underwent major reconstructive knee surgery and was tasked with performing seemingly outdated methods of rehab, inspiring the invention of this product as a preventative and athletic-enhancing device. RPM2 has undergone extensive validity testing using today's clinical standards in gait analysis at Texas A&M University Corpus Christi, and provides athletes with a competitive edge by helping correct improper mechanics, increase performance and prevent injury, ultimately maximizing bilateral equivalence/symmetry.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/medhab-llc-establishes-partnership-with-olympic-champion-michael-d-johnson-and-michael-johnson-performance-inc-929795077.html
SOURCE MedHab, LLC.